Experimental migraine models and their relevance in migraine therapy

Cephalalgia

Volumn 26, Issue 6, 2006, Pages 642-659

  Arulmani, U ^a   Gupta, S ^a   MaassenVanDenBrink, A ^a   Centurion D ^b   Villalon C M ^b   Saxena, P R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Antimigraine drugs; Arteriovenous anastomoses; Dihydroergotamine; Ergotamine; Experimental model; Migraine; Pig; Triptans

Indexed keywords

4991W93; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIMIGRAINE AGENT; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; DIHYDROERGOTAMINE; DIZOCILPINE; DONITRIPTAN; ELETRIPTAN; ERGOT ALKALOID; ERGOTAMINE; FROVATRIPTAN; GANAXOLONE; LANEPITANT; MEMANTINE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; OLCEGEPANT; OPIATE DERIVATIVE; PARTHENOLIDE; PHENYLEPHRINE; PNU 142633F; SEROTONIN; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

BRAIN BLOOD FLOW; BRAIN STEM; CLINICAL TRIAL; ELECTROSTIMULATION; EXPERIMENTAL MODEL; EXTRAVASATION; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MIGRAINE; MIGRAINE AURA; NERVE STIMULATION; NEUROGENIC INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SUPERIOR SAGITTAL SINUS; SWINE; THORAX DISEASE; TRIGEMINAL NERVE; TRIGEMINUS GANGLION; VASCULARIZATION; VASODILATATION;

EID: 33745203001     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.01082.x     Document Type: Review

References (157)

1. Ophoff RA, Van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol 2001 413 : 1 10.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002 346 : 257 70.
3. Silberstein SD. Migraine. Lancet 2004 363 : 381 91.
4. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004 24 ( Suppl. 2 2 7.
5. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004 24 : 611 22.
6. 1B/1D receptor agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA, editors. The headaches. Philadelphia: Lippincott Williams & Wilkins 2005 6: 469 503.
7. Buzzi MG, Tassorelli C, Nappi G. Peripheral and central activation of trigeminal pain pathways in migraine: data from experimental animal models. Cephalalgia 2003 23 ( Suppl. 1 1 4.
8. Parsons AA, Bingham S. The search for novel migraine therapies: experimental models. Funct Neurol 2000 15 ( Suppl. 3 36 42.
9. Spierings ELH. Pathogenesis of the migraine attack. Clin J Pain 2003 19: 255 62.
10. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000 47: 614 24.
11. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 2002 45: 199 210.
12. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995 1: 658 60.
13. Welch KM. Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 2003 24 ( Suppl. 2 S149 53.
14. Lauritzen M. Cortical spreading depression in migraine. Cephalalgia 2001 21: 757 60.
15. Spierings ELH. The aura-headache connection in migraine: a historical analysis. Arch Neurol 2004 61: 794 9.
16. James MF, Smith JM, Boniface SJ, Huang CL, Leslie RA. Cortical spreading depression and migraine: new insights from imaging? Trends Neurosci 2001 24: 266 71.
17. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969 2: 1 28.
18. De Vries P, Villalón CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999 375: 61 74.
19. Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond) 2001 100: 215 20.
20. Tsimikas S. Transcatheter closure of patent foramen ovale for migraine prophylaxis: hope or hype? J Am Coll Cardiol 2005 45: 496 8.
21. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005 45: 489 92.
22. Monteiro JM, Rosas MJ, Correia AP, Vaz AR. Migraine and intracranial vascular malformations. Headache 1993 33: 563 5.
23. Troost BT, Mark LE, Maroon JC. Resolution of classic migraine after removal of an occipital lobe AVM. Ann Neurol 1979 5: 199 201.
24. Bruyn GW. Intracranial arteriovenous malformation and migraine. Cephalalgia 1984 4: 191 207.
25. Silvestrini M, Cupini LM, Calabresi P, Floris R, Bernardi G. Migraine with aura-like syndrome due to arteriovenous malformation. The clinical value of transcranial Doppler in early diagnosis. Cephalalgia 1992 12: 115 9.
26. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998 79: 964 82.
27. 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004 101 : 4274 9.
28. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 1983 13 : 32 7.
29. Drummond PD, Lance JW. Facial temperature in migraine, tension-vascular and tension headache. Cephalalgia 1984 4 : 149 58.
30. Saxena PR. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models, Vol. 27. Philadelphia : Lippincott-Raven Publishers 1995 : 189 98.
31. Hales JRS. Radioactive microsphere techniques for studies of the circulation. Clin Exp Pharmacol Physiol 1974 1 : 31 46.
32. Den Boer MO, Van Woerkens LJ, Somers JA, Duncker DJ, Lachmann B, Saxena PR, Verdouw PD. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 1993 75 : 782 9.
33. 1B/1D and novel receptors. Br J Pharmacol 1998 123 : 1561 70.
34. 1D receptor antagonist. Br J Pharmacol 1996 118 : 85 92.
35. 2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 1999 127 : 1263 71.
36. 1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998 358 : 212 9.
37. Tom B, De Vries P, Heiligers JP, Willems EW, Kapoor K, John GW, Saxena PR. Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs. Cephalalgia 2002 22 : 37 47.
38. Villalón CM, Ramirez-San Juan E, Castillo C, Castillo E, Lopez-Munóz FJ, Terrón JA. Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br J Pharmacol 1995 116 : 2778 84.
39. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 1989 96 : 83 90.
40. Saxena PR. Selective carotid vasoconstriction by ergotamine as a relevant mechanism in its antimigraine action. Arch Neurobiol (Madr) 1974 37 ( Suppl. 301 15.
41. 2-adrenoceptors. Br J Pharmacol 1999 126 : 585 94.
42. 1D receptor antagonist. Behav Brain Res 1996 73 : 157 61.
43. 1D receptor subtype. Naunyn Schmiedebergs Arch Pharmacol 1996 354 : 550 6.
44. 7 receptor. Br J Pharmacol 1997 120 : 1319 27.
45. 1D (BRL15572) receptor antagonists. Eur J Pharmacol 1998 362 : 69 72.
46. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 60 : 1259 87.
47. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003 43 : 144 66.
48. Saxena PR, de Vlaam-Schluter GM. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine - studies in an experimental model for migraine. Headache 1974 13 : 142 63.
49. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994 46 : 157 203.
50. Willems EW, Valdivia LF, Ramirez-San Juan E, Saxena PR, Villalón CM. Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline. Life Sci 2001 69 : 143 53.
51. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001 53 : 319 56.
52. 2A/2C- adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 2004 484 : 287 90.
53. 1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs. Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 46 53.
54. Willems EW, Valdivia LF, Villalón CM, Saxena PR. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 2003 23 : 245 57.
55. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990 28 : 183 7.
56. Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003 106 : 461 70.
57. Iversen HK. Human migraine models. Cephalalgia 2001 21 : 781 5.
58. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002 22 : 54 61.
59. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002 137 : 62 8.
60. 1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995 6 : 1475 9.
61. Kruuse C, Jacobsen TB, Lassen LH, Thomsen LL, Hasselbalch SG, Dige-Petersen H, Olesen J. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000 20 : 1372 9.
62. De Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003 73 : 312 21.
63. Van Es NM, Bruning TA, Camps J, Chang PC, Blauw GJ, Ferrari MD et al. Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia 1995 15 : 288 91.
64. 1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000 68 : 418 26.
65. 1F-receptor activation. Br J Clin Pharmacol 1999 47 : 75 82.
66. 1B- immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997 17 : 833 42.
67. 1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol 1998 124 : 1345 54.
68. Van den Broek RW, MaassenVanDenBrink A, De Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol 2000 407 : 165 73.
69. Gulbenkian S, Cuhmna E, Sa M, Pinto Barosso C, Edvinsson L. Innervation of intracranial blood vessels. London : Martin Dunitz Ltd. 1999.
70. 1B-receptors. Br J Clin Pharmacol 1998 46 : 577 82.
71. 2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996 8 : 959 67.
72. Totaro R, De Matteis G, Marini C, Baldassarre M, Carolei A. Sumatriptan and cerebral blood flow velocity changes during migraine attacks. Headache 1997 37 : 635 9.
73. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991 12 : 444 6.
74. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 2003 481 : 207 16.
75. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002 434 : 49 53.
76. 2,7)]hCGRP-preferring receptor. Eur J Pharmacol 2000 400 : 313 9.
77. Wu D, Doods H, Arndt K, Schindler M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem Soc Trans 2002 30 : 468 73.
78. 1 receptors in the guinea pig basilar artery. Eur J Pharmacol 2001 414 : 249 58.
79. Gupta S, Mehrotra S, Villalón CM, Garrelds IM, De Vries R, Van Kats JP, et al. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 2006 : in press.
80. Franco-Cereceda A, Rudehill A, Lundberg JM. Calcitonin gene-related peptide but not substance P mimics capsaicin-induced coronary vasodilation in the pig. Eur J Pharmacol 1987 142 : 235 43.
81. Brown EG, Endersby CA, Smith RN, Talbot JC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991 31 : 339 44.
82. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996 16 : 554 9.
83. Saxena PR, Tfelt-Hansen P. Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches, Vol. 45. New York : Raven Press Ltd 1993 : 329 41.
84. MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000 55 : 1524 30.
85. 1B/1D agonist frovatriptan. Headache 2002 42 ( Suppl. 2 S47 S53.
86. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001 21 : 804 12.
87. Van den Broek RWM, MaassenVanDenBrink A, Mulder PG, Bogers AJJC, Avezaat CJ, John GW, Saxena PR. Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Eur J Pharmacol 2002 443 : 125 32.
88. Hasbak P, Saetrum Opgaard O, Eskesen K, Schifter S, Arendrup H, Longmore J, Edvinsson L. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 2003 304 : 326 33.
89. Xiao L, Lu R, Hu CP, Deng HW, Li YJ. Delayed cardioprotection by intestinal preconditioning is mediated by calcitonin gene-related peptide. Eur J Pharmacol 2001 427 : 131 5.
90. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001 53 : 167 78.
91. 1B/1D receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. CNS Drugs 1998 10 : 271 86.
92. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993 43 : S16 S20.
93. 1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology 1997 36 : 83 91.
94. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997 36 : 525 33.
95. 1B receptors. Mol Pharmacol 1996 49 : 761 5.
96. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997 8 : 2237 40.
97. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997 61 : 2117 26.
98. 1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001 358 : 1230 4.
99. 1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 1999 38 : 1043 53.
100. Cutrer FM, O'Donnell A, Sanchez del Rio M. Functional neuroimaging: enhanced understanding of migraine pathophysiology. Neurology 2000 55 : S36 S45.
101. Brandli P, Loffler BM, Breu V, Osterwalder R, Maire JP, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996 64 : 315 22.
102. 2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater. Eur J Pharmacol 1994 263 : 193 8.
103. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997 17 : 785 90.
104. Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000 47 : 238 41.
105. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996 67 : 375 8.
106. Data J, Britch N, Westergaard N, Weihmuller F, Harris S, Swarz H et al. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenstrual females. Headache 1998 38 : 380.
107. May A, Shepheard SL, Knorr M, Effert R, Wessing A, Hargreaves RJ et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998 121 : 1231 7.
108. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet 2001 357 : 1016 7.
109. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997 17 : 153 8 discussion 43.
110. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin 1997 15 : 27 42.
111. Goadsby PJ. Is a central action of acute antimigraine drugs essential? Cephalalgia 1997 17 ( Suppl. 17 10 1.
112. Goadsby PJ, Boes CJ. Zolmitriptan: differences from sumatriptan. Curr Med Res Opin 2001 17 ( Suppl. 1 S46 S50.
113. 1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology 2002 42 : 374 85.
114. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002 953 : 181 8.
115. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996 119 : 249 56.
116. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997 328 : 37 40.
117. Harper AM, MacKenzie ET, McCulloch J, Pickard JD. Migraine and the blood-brain barrier. Lancet 1977 1 : 1034 6.
118. 1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 1995 34 : 255 61.
119. Hamalainen ML, Autti T, Salonen O, Santavuori P. Brain MRI in children with migraine: a controlled morphometric study. Cephalalgia 1996 16 : 541 4.
120. Alvarez-Cermeno J, Gobernado JM, Aimeno A. Transient blood-brain barrier (BBB) damage in migraine. Headache 1986 26 : 437.
121. Ramadan NM. The link between glutamate and migraine. CNS Spectr 2003 8 : 446 9.
122. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004 24 : 596 602.
123. Filla SA, Winter MA, Johnson KW, Bleakman D, Bell MG, Bleisch TJ et al. Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar-bonylimidazol-1-ylmethyl) decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J Med Chem 2002 45 : 4383 6.
124. Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998 76 : 239 48.
125. Clayton JS, Gaskin PJ, Beattie DT. Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig. Brain Res 1997 775 : 74 80.
126. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995 116 : 3199 204.
127. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002 51 : 507 16.
128. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994 269 : 4705 8.
129. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000 3 : 509 14.
130. Diener HC, Hartung E, Chrubasik J, Evers S, Schoenen J, Eikermann A et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001 21 : 120 8.
131. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996 384 : 560 4.
132. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004 55 : 27 36.
133. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000 123 : 1703 9.
134. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004 366 : 241 4.
135. Anderson TR, Andrew RD. Spreading depression: imaging and blockade in the rat neocortical brain slice. J Neurophysiol 2002 88 : 2713 25.
136. Faria LC, Mody I. Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortex. J Neurophysiol 2004 92 : 2610 4.
137. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat - intravital microscope studies. Cephalalgia 1997 17 : 525 31.
138. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 1997 17 : 518 24.
139. B receptors in carotid vasodilatation. Br J Pharmacol 1999 126 : 485 93.
140. Beattie DT, Connor HE. The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs. Br J Pharmacol 1994 112 : 262 6.
141. 1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 2003 140 : 718 24.
142. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004 143 : 1074 5.
143. Fusco M, D'Andrea G, Micciche F, Stecca A, Bernardini D, Cananzi AL. Neurogenic inflammation in primary headaches. Neurol Sci 2003 24 ( Suppl. 2 S61 S4.
144. Jansen I, Alafaci C, Uddman R, Edvinsson L. Evidence that calcitonin gene-related peptide contributes to the capsaicin-induced relaxation of guinea pig cerebral arteries. Regul Pept 1990 31 : 167 78.
145. O'Shaughnessy CT, Waldron GJ, Connor HE. Lack of effect of sumatriptan and UK-14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery. Br J Pharmacol 1993 108 : 191 5.
146. Kapoor K, Arulmani U, Heiligers JP, Garrelds IM, Willems EW, Doods H et al. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 2003 140 : 329 38.
147. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999 51 : 159 212.
148. Sams-Nielsen A, Orskov C, Jansen-Olesen I. Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals. Br J Pharmacol 2001 132 : 1145 53.
149. 2+ channel gene CACNL1A4. Cell 1996 87 : 543 52.
150. +-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003 54 : 360 6.
151. Kors EE, Vanmolkot KR, Haan J, Frants RR, Van den Maagdenberg AM, Ferrari MD. Recent findings in headache genetics. Curr Opin Neurol 2004 17 : 283 8.
152. Wessman M, Kaunisto MA, Kallela M, Palotie A. The molecular genetics of migraine. Ann Med 2004 36 : 462 73.
153. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005 366 : 371 7.
154. Van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004 41 : 701 10.
155. Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004 8 : 91 5.
156. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 44 : 35 42 discussion 3.
157. Golumbek PT, Rho JM, Spain WJ, van Brederode JF. Effects of flunarizine on spontaneous synaptic currents in rat neocortex. Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 176 82.